The original success of the copyright undeniably transformed the pharmaceutical landscape, but betting in companies strongly reliant on off-patent versions presents a complex picture. Despite early returns were significant, the expiration of patents and the rise of cheaper alternatives have weakened market share. Therefore, a thorough analysis of o